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Reply. 
 We thank Hirten and Colombel for their erudite commentary on our recently 
published work.1, 2 The findings of our study highlight the association between irritable bowel 
syndrome (IBS)-type symptoms, in patients with quiescent inflammatory bowel disease 
(IBD), and psychological co-morbidity and poor quality of life, and are in keeping with those 
of another large study from Sweden, reporting that 18% of patients with ulcerative colitis 
(UC) in deep remission report these symptoms.3 These studies highlight a hitherto poorly 
characterized cohort of patients with unmet needs, for which the therapeutic options are 
limited.  
In response to their specific comments, firstly we acknowledged that the use of fecal 
calprotectin (FC) as an objective measure of inflammatory disease activity is contentious, as 
is the cut-off used to define disease activity. However, the routine use of ileocolonoscopy and 
small bowel imaging in a cross-sectional study of 378 patients is impractical and potentially 
unethical, given that 60% of patients did not have clinically active disease at the time of 
participation. We used a FC cut-off of ≥250µg/g to define active disease, based on previous 
studies in this field and expert consensus.4-6 However, we conducted sensitivity analyses 
using a cut-off of ≥100µg/g. In these analyses, the proportion of patients with IBS-type 
symptoms was reduced, but the association between symptoms, psychological co-morbidity 
and poor quality of life remained. In addition, the mean FC in those with IBS-type symptoms 
in our primary analysis was <100µg/g in both Crohn's disease and UC.  
Secondly, we conceded that describing all patients as suffering from IBS may be 
misleading, particularly as similar symptoms secondary to other organic complaints such as 
bile acid malabsorption and small intestinal bacterial overgrowth may be the culprit,7, 8 
particularly in those with previous surgery, and that this may have inflated the prevalence of 
these symptoms. It may therefore be more accurate to describe these patients as reporting 
"persistent gastrointestinal (GI) symptoms in the absence of inflammation", rather than "IBS-
type symptoms". Indeed, within the same cohort of patients, subsequent analysis of the 
prevalence and impact of persistent GI symptoms in the absence of inflammation on 
psychological co-morbidity and quality of life demonstrated similar findings to those 
described in the present study, irrespective of whether these symptoms met Rome III criteria 
for IBS.9 
 Thirdly, Hirten and Colombel highlight the potential for misclassification of persistent 
symptoms in quiescent IBD as IBS, and that treatment of these patients should be tailored to 
the underlying cause, citing dysregulation of the enteric nervous system and enteric 
dysmotility, two of the cardinal features of the functional gastrointestinal disorders, as 
potential targets to therapy. To the best of our knowledge, evidence-based management 
strategies for these patholophysiologies are lacking in IBD, and it is this exact group of 
patients that our study successfully seeks to identify and better characterize. Thus, our 
findings highlight the need for trials of novel therapeutic interventions in these patients, and 
the requirement of a paradigm-shift in the approach towards their management. In the UK, 
there has been a recent call from the Health Technology Assessment for a trial of therapies 
for ongoing diarrhea and abdominal pain in patients with stable UC, which may help to 
address this deficit in current knowledge.10   
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